The DA VINCI study: is Ireland achieving ESC/EAS guideline-directed LDL-C goals?
File(s)
Published version
Author(s)
Type
Journal Article
Abstract
Background
The EU-wide, cross-sectional observational study of lipid-lowering therapy (LLT) use in secondary and primary care (DA VINCI) assessed the proportion of patients achieving low-density lipoprotein cholesterol (LDL-C) goals recommended by the European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) guidelines and provided an insight into regional use of LLT in Europe, including Ireland.
Aims
This analysis focuses on data from patients in Ireland who participated in the DA VINCI study.
Methods
The DA VINCI study enrolled patients receiving LLT at primary and secondary care sites across 18 European countries between June 2017 and November 2018. The study assessed the achievement of risk-based 2016 and 2019 ESC/EAS LDL-C goals. This subgroup analysis aimed to evaluate LDL-C goal attainment in an Irish cohort of primary and secondary care patients.
Results
In total, 198 patients from Ireland were enrolled from three primary care and three secondary care centres. Most patients were White and male, and were receiving moderate- or high-intensity statin therapy (most frequently atorvastatin or rosuvastatin). Few patients (< 10%) were receiving combination therapy of statin and ezetimibe. Approximately 60% of patients achieved their 2016 ESC/EAC LDL-C goals while less than half the patients achieved their 2019 ESC/EAS goals. Approximately half of secondary prevention patients achieved their 2016 ESC/EAS goals and only 20% of secondary prevention patients achieved their 2019 ESC/EAS goals.
Conclusions
These results highlight the disparity between dyslipidaemia management in clinical practice in Ireland and guideline recommendations.
Trial registration
ENCePP; EU PAS 22,075; date registered 06 February 2018.
The EU-wide, cross-sectional observational study of lipid-lowering therapy (LLT) use in secondary and primary care (DA VINCI) assessed the proportion of patients achieving low-density lipoprotein cholesterol (LDL-C) goals recommended by the European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) guidelines and provided an insight into regional use of LLT in Europe, including Ireland.
Aims
This analysis focuses on data from patients in Ireland who participated in the DA VINCI study.
Methods
The DA VINCI study enrolled patients receiving LLT at primary and secondary care sites across 18 European countries between June 2017 and November 2018. The study assessed the achievement of risk-based 2016 and 2019 ESC/EAS LDL-C goals. This subgroup analysis aimed to evaluate LDL-C goal attainment in an Irish cohort of primary and secondary care patients.
Results
In total, 198 patients from Ireland were enrolled from three primary care and three secondary care centres. Most patients were White and male, and were receiving moderate- or high-intensity statin therapy (most frequently atorvastatin or rosuvastatin). Few patients (< 10%) were receiving combination therapy of statin and ezetimibe. Approximately 60% of patients achieved their 2016 ESC/EAC LDL-C goals while less than half the patients achieved their 2019 ESC/EAS goals. Approximately half of secondary prevention patients achieved their 2016 ESC/EAS goals and only 20% of secondary prevention patients achieved their 2019 ESC/EAS goals.
Conclusions
These results highlight the disparity between dyslipidaemia management in clinical practice in Ireland and guideline recommendations.
Trial registration
ENCePP; EU PAS 22,075; date registered 06 February 2018.
Date Issued
2023-06-01
Date Acceptance
2022-06-02
Citation
Irish Journal of Medical Science, 2023, 192 (3), pp.1077-1084
ISSN
0021-1265
Publisher
Springer
Start Page
1077
End Page
1084
Journal / Book Title
Irish Journal of Medical Science
Volume
192
Issue
3
Copyright Statement
© The Author(s) 2022 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
License URL
Identifier
https://www.ncbi.nlm.nih.gov/pubmed/35776266
PII: 10.1007/s11845-022-03050-6
Subjects
CARDIOVASCULAR-DISEASE
CHOLESTEROL
COUNTRIES
General & Internal Medicine
Guidelines
Life Sciences & Biomedicine
Lipids
Low-density lipoprotein cholesterol
Medicine, General & Internal
RISK
Science & Technology
STATIN THERAPY
Statins
Publication Status
Published
Coverage Spatial
Ireland
Date Publish Online
2022-07-01